TY - JOUR A1 - Dresen, Ellen A1 - Lee, Zheng-Yii A1 - Hill, Aileen A1 - Notz, Quirin A1 - Patel, Jayshil J. A1 - Stoppe, Christian T1 - History of scurvy and use of vitamin C in critical illness: A narrative review JF - Nutrition in Clinical Practice N2 - In 1747, an important milestone in the history of clinical research was set, as the Scottish surgeon James Lind conducted the first randomized controlled trial. Lind was interested in scurvy, a severe vitamin C deficiency which caused the death of thousands of British seamen. He found that a dietary intervention with oranges and lemons, which are rich in vitamin C by nature, was effective to recover from scurvy. Because of its antioxidative properties and involvement in many biochemical processes, the essential micronutrient vitamin C plays a key role in the human biology. Moreover, the use of vitamin C in critical illness—a condition also resulting in death of thousands in the 21st century—has gained increasing interest, as it may restore vascular responsiveness to vasoactive agents, ameliorate microcirculatory blood flow, preserve endothelial barriers, augment bacterial defense, and prevent apoptosis. Because of its redox potential and powerful antioxidant capacity, vitamin C represents an inexpensive and safe antioxidant, with the potential to modify the inflammatory cascade and improve clinical outcomes of critically ill patients. This narrative review aims to update and provide an overview on the role of vitamin C in the human biology and in critically ill patients, and to summarize current evidence on the use of vitamin C in diverse populations of critically ill patients, in specific focusing on patients with sepsis and coronavirus disease 2019. KW - antioxidant KW - scurvy KW - sepsis KW - vitamin C KW - critical illness KW - COVID‐19 Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318176 VL - 38 IS - 1 SP - 46 EP - 54 ER - TY - THES A1 - Reifschläger, Leonie Sophie T1 - Analyse exosomaler microRNAs im Serum von Patientinnen mit Brustkrebsmetastasen T1 - Analysis of exosomal microRNAs in serum of patients with breast cancer metastases N2 - Das Mammakarzinom ist weltweit die häufigste krebsbedingte Todesursache bei Frauen. Fortschritte in der Therapie ermöglichen zwar eine Verlängerung der Lebens- dauer, jedoch kommt es dadurch vermehrt zur Bildung von Metastasen im zentralen Nervensystem (ZNS). Die Diagnostik und Behandlung von ZNS-Metastasen sind be- grenzt und die Lebensqualität sowie Lebensdauer der Betroffenen nimmt bei zerebraler Metastasierung rapide ab. Ziel aktueller Forschungsprojekte ist daher, Biomarker zu identifizieren, die Hinweise auf eine Brustkrebserkrankung oder Metastasierung liefern. So soll eine kostengünstige, risikoarme und minimalinvasive Methode etabliert werden, die zuverlässige Daten über die Prognose und dementsprechende Therapien erbringt. Diese Arbeit hatte daher die Absicht, mithilfe von qPCR Expressionsprofile von miRNAs aus Serumproben von Brustkrebspatientinnen zu erstellen und deren Funktion als prog- nostische Biomarker für eine Metastasierung ins ZNS zu erweisen. Anhand von Metas- tasierung und Rezeptorstatus wurden die Proben in Untergruppen eingeteilt und statis- tisch mit einer gesunden Kontrollgruppe verglichen. Insgesamt zeigte sich bei 26 miRNAs eine signifikante Dysregulation der Expression bei mindestens einer der Untergruppen. Insbesondere bei ZNS-Metastasen war das Expres- sionsmuster bei miRNA-122-5p, miRNA-296-5p, miRNA-490-3p und miRNA-576-3p sig- nifikant erhöht, während die Expression von miRNA-130a-3p, miRNA-148b-3p und miRNA-326 signifikant reduziert war. Basierend auf den Übereinstimmungen unserer Er- gebnisse mit den Daten bisheriger Forschungsprojekten wiesen vier miRNAs eine po- tenzielle Funktion als Biomarker für Metastasen auf: miRNA-122-5p, miRNA-490-3p und miRNA-130a-3p, miRNA-326. Bei ZNS-Metastasen zeigten besonders miRNA-122-5p und miRNA-490-3p statistisch relevante Veränderungen. Um den Einfluss von miRNAs auf den gesamten Körper darzustellen, wurde mithilfe ver- schiedener Datenbanken nach entsprechenden Zielgenen und Signalwegen für die 26 identifizierten miRNAs recherchiert. Neben dem Einfluss auf Stoffwechselwege und Er- krankungen, zeigte sich bei acht Targets ein Zusammenhang mit der Entstehung von Krebs. Ergänzend zur Identifikation von miRNA-Expressionsprofilen wurden Zellkulturversuche mit zerebralen Endothel- (cerebEND) und Brustkrebszellen (4T1) durchgeführt. Verwendet wurden zwei cerebEND- und eine 4T1-Zellreihe von Mäusen, von denen eine ce- rebEND-Kultur zuvor in der Arbeitsgruppe Burek mit einem miRNA-210-Vektor trans- fiziert wurde. Studien belegen den Einfluss von miRNA-210 auf den mitochondrialen Stoffwechsel, Angiogenese, Reaktionen auf DNA-Schäden, Apoptose und Zellüberleben sowie auf die Proteine BRCA1, PARP1 und E-Cadherin und schreiben ihr damit eine Funktion in der Krebsentstehung und Metastasierung zu. Zur Bestimmung der Proliferation und Aktivität der transfizierten cerebEND-210-Zellen im Verhältnis zur unbehandelten Kontrolle, wurden BrdU-Proliferationsassays und MTT- Assays mit verschiedenen Zellzahlen durchgeführt. Bei der Untersuchung der Prolifera- tion zeigte sich in beiden Versuchen eine erhöhte Aktivität der cerebEND-210-Zellen, da miRNA-210 vermutlich auch hier das Zellüberleben gesichert hat. Zudem wurde die An- heftung der Brustkrebszellen an den zerebralen Endothelzellen im Adhäsionsversuchs überprüft. Hierbei wurde eine Abnahme der Adhäsion der cerebEND-210-Zellen beo- bachtet. Vermutet wird eine Veränderung des Phänotyps der Rezeptorbindungen der cerebEND-210-Zellen. Die Ergebnisse der Zellkulturversuche dienen als Grundlage für weitere Experimente. N2 - Breast cancer is the most common cause of cancer-related death in women worldwide. Although advances in therapy allow for increased longevity, this results in increased metastasis to the central nervous system (CNS). Diagnosis and treatment of CNS metastases are limited and the quality of life and lifespan of those affected decreases rapidly with cerebral metastasis. Therefore, the goal of current research projects is to identify biomarkers that provide evidence of breast cancer disease or metastasis. Thus, a low-cost, low-risk, and minimally invasive method should be established that yields reliable data on prognosis and corresponding therapies. Therefore, this work aimed to use qPCR to establish expression profiles of miRNAs from serum samples of breast cancer patients and prove their function as prognostic biomarkers for metastasis to the CNS. Based on metastasis and receptor status, samples were divided into subgroups and statistically compared with a healthy control group. Overall, 26 miRNAs showed significant dysregulation of expression in at least one of the subgroups. Specifically, in CNS metastases, the expression pattern of miRNA-122-5p, miRNA-296-5p, miRNA-490-3p and miRNA-576-3p was significantly increased, while the expression of miRNA-130a-3p, miRNA-148b-3p and miRNA-326 was significantly decreased. Based on the agreements of our results with the data of previous research projects, four miRNAs showed potential function as biomarkers of metastasis: miRNA-122-5p, miRNA-490-3p and miRNA-130a-3p, miRNA-326. In CNS metastases, miRNA-122-5p and miRNA-490-3p in particular showed statistically relevant changes. To demonstrate the influence of miRNAs on the whole body, we searched for corresponding target genes and signaling pathways for the 26 identified miRNAs using various databases. In addition to their influence on metabolic pathways and diseases, eight targets were found to be associated with the development of cancer. Complementary to the identification of miRNA expression profiles, cell culture experiments were performed with cerebral endothelial (cerebEND) and breast cancer (4T1) cells. Two cerebEND and one 4T1 cell lines from mice were used, one cerebEND culture of which was previously transfected with a miRNA-210 vector in the Burek group. Studies demonstrate the influence of miRNA-210 on mitochondrial metabolism, angiogenesis, DNA damage responses, apoptosis and cell survival, as well as on BRCA1, PARP1 and E-cadherin proteins, thus attributing it a function in carcinogenesis and metastasis. To determine the proliferation and activity of the transfected cerebEND-210 cells relative to the untreated control, BrdU proliferation assays and MTT assays were performed with different cell numbers. Proliferation assays showed increased activity of cerebEND-210 cells in both experiments, as miRNA-210 presumably ensured cell survival in this case as well. In addition, the attachment of breast cancer cells to cerebral endothelial cells was examined in the adhesion assay. Here, a decrease in adhesion of cerebEND-210 cells was observed. A change in the phenotype of receptor binding of cerebEND-210 cells is suspected. The results of the cell culture experiments serve as a basis for further experiments. KW - miRNS KW - Exosom KW - Blut-Hirn-Schranke KW - Hirnmetastasen KW - Breastcancer KW - Blood-Brain-Barrier KW - miRNA KW - Brustkrebs KW - Mammakarzinom Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-313987 ER - TY - JOUR A1 - Weibel, Stephanie A1 - Popp, Maria A1 - Reis, Stefanie A1 - Skoetz, Nicole A1 - Garner, Paul A1 - Sydenham, Emma T1 - Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis JF - Research Synthesis Methods N2 - Evidence synthesis findings depend on the assumption that the included studies follow good clinical practice and results are not fabricated or false. Studies which are problematic due to scientific misconduct, poor research practice, or honest error may distort evidence synthesis findings. Authors of evidence synthesis need transparent mechanisms to identify and manage problematic studies to avoid misleading findings. As evidence synthesis authors of the Cochrane COVID-19 review on ivermectin, we identified many problematic studies in terms of research integrity and regulatory compliance. Through iterative discussion, we developed a research integrity assessment (RIA) tool for randomized controlled trials for the update of this Cochrane review. In this paper, we explain the rationale and application of the RIA tool in this case study. RIA assesses six study criteria: study retraction, prospective trial registration, adequate ethics approval, author group, plausibility of methods (e.g., randomization), and plausibility of study results. RIA was used in the Cochrane review as part of the eligibility check during screening of potentially eligible studies. Problematic studies were excluded and studies with open questions were held in awaiting classification until clarified. RIA decisions were made independently by two authors and reported transparently. Using the RIA tool resulted in the exclusion of >40% of studies in the first update of the review. RIA is a complementary tool prior to assessing “Risk of Bias” aiming to establish the integrity and authenticity of studies. RIA provides a platform for urgent development of a standard approach to identifying and managing problematic studies. KW - COVID-19 pandemic KW - systematic review KW - research integrity KW - randomized controlled trial KW - good clinical practice KW - evidence synthesis Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318236 VL - 14 IS - 3 SP - 357 EP - 369 ER - TY - JOUR A1 - Dresen, Ellen A1 - Pimiento, Jose M. A1 - Patel, Jayshil J. A1 - Heyland, Daren K. A1 - Rice, Todd W. A1 - Stoppe, Christian T1 - Overview of oxidative stress and the role of micronutrients in critical illness JF - Journal of Parenteral and Enteral Nutrition N2 - Inflammation and oxidative stress represent physiological response mechanisms to different types of stimuli and injury during critical illness. Its proper regulation is fundamental to cellular and organismal survival and are paramount to outcomes and recovery from critical illness. A proper maintenance of the delicate balance between inflammation, oxidative stress, and immune response is crucial for resolution from critical illness with important implications for patient outcome. The extent of inflammation and oxidative stress under normal conditions is limited by the antioxidant defense system of the human body, whereas the antioxidant capacity is commonly significantly compromised, and serum levels of micronutrients and vitamins significantly depleted in patients who are critically ill. Hence, the provision of antioxidants and anti-inflammatory nutrients may help to reduce the extent of oxidative stress and therefore improve clinical outcomes in patients who are critically ill. As existing evidence of the beneficial effects of antioxidant supplementation in patients who are critically ill is still unclear, actual findings about the most promising anti-inflammatory and antioxidative candidates selenium, vitamin C, zinc, and vitamin D will be discussed in this narrative review. The existing evidence provided so far demonstrates that several factors need to be considered to determine the efficacy of an antioxidant supplementation strategy in patients who are critically ill and indicates the need for adequately designed multicenter prospective randomized control trials to evaluate the clinical significance of different types and doses of micronutrients and vitamins in selected groups of patients with different types of critical illness. KW - critical illness KW - vitamins KW - vitamin C KW - inflammation KW - medical nutrition therapy KW - oxidative stress KW - selenium KW - trace elements KW - micronutrients KW - vitamin D KW - zinc Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318186 VL - 47 SP - S38 EP - S49 ER - TY - THES A1 - Leopold, Natalia T1 - Einfluss der peripheren Entzündung auf die Permeabilität des Perineuriums im \({N.}\) \(ischiadicus\) sowie auf das lokale Hinterpfotengewebe im FCA-Entzündungsmodell T1 - Influence of a peripheral inflammation on the permeability of the perineurium in the sciatic nerve as well as on the local hind paw tissue in the FCA inflammation model N2 - In früheren Studien wurde gezeigt, dass durch eine mit FCA-induzierte Pfotenentzündung die Permeabilität für hydrophile Analgetika der kleinen Nerven am Entzündungsort zunimmt. In der vorliegenden Arbeit wurden spezifische Veränderungen von Barriereproteinen des Perineuriums und der Schwannschen Zellen und ihren Regulatoren nach intraplantarer Injektion von FCA lokal in die Hinterpfote und proximal am N. ischiadicus untersucht. Aus früheren Studien ist bekannt, dass vor allem Claudin-1 das Perineurium abdichtet. Daher konzentrierte sich die Arbeit auf Claudin-1 und einen möglichen Einfluss von Claudin-19 aus Schwannschen Zellen. Alle Untersuchungen erfolgten an Wister-Ratten. Zwei Stunden bis 96 Stunden nach der FCA-Injektion in die Hinterpfote waren die Expression sowie die Immunreaktivität von Claudin-1 und die Expression von Claudin-19 im ipsilateralen proximalen Ischiasnerv unverändert. Zudem wurde keine Penetration des Farbstoffes EBA in das Endoneurium und in den Ischiasnerv nach ex vivo Applikation nachgewiesen, was auf eine gute Abdichtung des Perineuriums hinweist. In der entzündeten Pfote selbst allerdings nahm die Expression von Claudin-1 und Claudin-19 ab. Parallel dazu kam es zu einer starken Abnahme des Co-Transkriptionsfaktors β-Catenin in der Pfote, aber nicht im Nerven. β-Catenin steuert die Expression von Claudin-1. Die Behandlung mit einem GSK3 β-Inhibitor bremste die Herunterregulation von Claudin-1 24 Stunden nach der intraplantaren Injektion von FCA ins Hinterpfotengewebe und führte zu einem Wiederanstieg der Konzentration. Daher kann abschließend festgehalten werden, dass eine periphere Entzündung zwar wie erwartet lokal die Barriere öffnet, es aber proximal nicht zu einer Barrierestörung kommt. Dies ist bei der Blut-Hirn-Schranke anders. Diese wird vermutlich über lösliche Faktoren bei Entzündung oder bei Nervenschäden, bei denen sich auch die Barriere im Spinalganglion verändert, durchlässiger. N2 - Previous studies have shown that FCA-induced paw inflammation increases the permeability to hydrophilic analgesics of the small nerves at the site of inflammation. In the present study, specific changes in barrier proteins of the perineurium and Schwann cells and their regulators were investigated following intra-plantar injection of FCA locally into the hind paw and proximally at the sciatic nerve (N. ischiadicus). It is known from previous studies that primarily claudin-1 seals the perineurium. Therefore, the study focused on claudin-1 and a possible influence of claudin-19 from Schwann cells. All examinations were carried out on Wister rats. Two hours to 96 hours after FCA injection into the hind paw, the expression as well as the immunoreactivity of claudin-1 and the expression of claudin-19 in the ipsilateral proximal sciatic nerve were unchanged. In addition, no penetration of the dye EBA intothe endoneurium and sciatic nerve was detected after ex vivo application, indicating a good seal of the perineurium. In the inflamed paw itself, however, the expression of claudin-1 and claudin-19 decreased. In parallel, there was a strong decrease in the co-transcription factor β-catenin in the paw, but not in the nerve. β-catenin controls the expression of claudin-1. Treatment with a GSK3 β inhibitor slowed down the down-regulation of claudin-1 24 hours after intra-plantar injection of FCA into the hind-paw tissue and resulted in a renewed rise in the concentration. Therefore, it can be concluded that although peripheral inflammation opens the barrier locally, as expected, there is no barrier disruption proximally. This is different for the blood-brain barrier. This probably becomes more permeable via soluble factors in the case of inflammation or nerve damage, in which the barrier in the spinal ganglion also changes. KW - perineurium KW - claudin 1 KW - Entzündungsmodell Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-322273 ER - TY - THES A1 - Sitter, Magdalena Maria T1 - Intensivmedizinische Behandlungen bei SARS-CoV-2 in der Schwangerschaft - Daten aus dem CRONOS-Register T1 - Intensive Care Treatment at SARS-CoV-2 Infection during Pregnancy — First Data from the CRONOS-Registry N2 - Mit dem Auftreten des SARS-CoV-2 Virus im Jahr 2020 war der Informationsgewinn für vulnerable Patientengruppen essentiell. Ziel dieser Arbeit war es maternale Charakteristika und das klinische Bild SARS-CoV-2 positiver Frauen mit Notwendigkeit einer intensivmedizinischen Behandlung während der Schwangerschaft und postpartal darzustellen, und diese Kohorte mit den SARS-CoV-2 positiven Schwangeren ohne intensivmedizinischen Handlungsbedarf zu vergleichen. Die Daten stammten aus dem deutschen CRONOS-Register, einem prospektiven, multizentrischen Register für SARS-CoV-2 positive schwangere Frauen. Eingeschlossen wurden alle schwangeren und postpartalen Frauen, die während ihrer SARS-CoV-2 Infektion auf eine ITS aufgenommen wurden. Diese wurden hinsichtlich maternaler Charakteristika, Krankheitsverlauf, sowie Outcomes verglichen. In 101 von 2650 Fällen (4%) der Patientinnen des CRONOS-Registers, kam es zu einer Aufnahme auf die ITS. Als invasivste Form der COVID-19 Behandlung war bei 6 Patientinnen nur eine Überwachung notwendig, 30 Patientinnen benötigten eine Sauerstoffinsufflation, 22 wurden nicht-invasiv beatmet, 28 erhielten eine invasive Beatmung und bei 15 Frauen wurde die Behandlung zur ECMO-Therapie eskaliert. Es wurden keine klinisch signifikanten Unterschiede zwischen Patientinnen gefunden, die unterschiedliche Behandlungsformen benötigten. Die Gruppe der ITS und Non-ITS Patientinnen unterschied sich statistisch signifikant beim Einfluss von Alter, BMI bei Einschluss und der Herkunft. Die Prävalenz der Frühgeburtlichkeit war unter den invasiv behandelten Patientinnen signifikant höher und auch im Vergleich der ITS mit den Non-ITS Patientinnen zeigte sich ein signifikanter Unterschied. Vier Frauen verstarben an COVID-19 und sechs Feten der ITS-Gruppe waren Totgeburten. Diese Kohorte zeigt, dass schwere COVID-19 Erkrankung bei schwangeren Frauen und Wöchnerinnen selten sind. Die Frühgeburtenrate ist hoch und COVID-19 mit Notwendigkeit einer Atemunterstützung erhöht das Risiko für ein schlechtes maternales und neonatales Outcome. Unter anderem ein höheres Alter und BMI sind mit einem höheren Risiko für eine ITS-Aufnahme verbunden. N2 - With the spreading of the SARS-CoV-2 virus in the year 2020, gain of information regarding vulnerable groups of patients was essential. We aimed to describe maternal characteristics and clinical presentation of SARS-CoV-2 positive women requiring intensive care treatment for COVID-19 during pregnancy and postpartum period, based on data of a comprehensive German surveillance system in obstetric patients. Data from COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS), a prospective multicenter registry for SARS-CoV-2 positive pregnant women, was analyzed with respect to ICU treatment. All women requiring intensive care treatment for COVID-19 were included and compared regarding maternal characteristics, course of disease, as well as maternal and neonatal outcomes. Also the ICU-cohort was compared to the cohort of pregnant and postpartum women not requiring intensive care treatment searching for characteristics and risk factors. Of 2650 cases in CRONOS, 101 women (4%) had a documented ICU stay. As the most invasive form of COVID-19 treatment interventions, patients received either continuous monitoring of vital signs without further treatment requirement (n = 6), insufflation of oxygen (n = 30), non-invasive ventilation (n = 22), invasive ventilation (n = 28), or escalation to extracorporeal membrane oxygenation (n = 15). No significant clinical differences were identified between patients receiving different forms of ventilatory support for COVID-19. Prevalence of preterm delivery was significantly higher in women receiving invasive respiratory treatments as well as in women receiving intensive care treatment in general. Four women died of COVID-19 and six fetuses were stillborn. Our cohort shows that progression of COVID-19 in pregnant and postpartum women with admission to ICU is rare. Preterm birth rate is high and COVID-19 requiring respiratory support increases the risk of poor maternal and neonatal outcome. Admission to ICU in this cohort was associated with a higher maternal age and maternal BMI before pregnancy. KW - Schwangerschaft KW - Intensivmedizin KW - COVID-19 KW - SARS-CoV-2 KW - Pregnancy KW - Critical Care Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325462 ER - TY - THES A1 - Rösing, Nils T1 - Neuroprotektive Effekte von Isosteviol-Natrium in einem in vitro Modell des Schlaganfalls T1 - Neuroprotective effects of isosteviol sodium in an in vitro model of stroke N2 - Ziel dieser Arbeit war der Nachweis eines neuroprotektiven Effektes von STVNA auf cerebEND Zellen der Maus in einem in vitro Modell des Schlaganfalls. Mit dem Verfahren zur Herstellung von STVNA konnte ein reines und im Vergleich zu Isosteviol in Wasser gut lösliches Produkt hergestellt werden, das die Anforderungen an eine Versuchssubstanz in einem in vitro Modell voll erfüllen konnte. Als in vitro Modell wurde das bereits bewährte Verfahren der OGD gewähl. CerebEND Zellen der Maus wurden für 4 h OGD ausgesetzt und anschließend für 4 h und 24 h mit 0, 1, 5, 10 und 20 mg/l STVNA behandelt. Direkt, 4 h und 24 h nach 4 h OGD wurden die jeweiligen Zellen geerntet und mittels Western Blot und qRT-PCR ausgewertet. Es wurden eine erhöhte Expression der Tight-Junction-Proteine Claudin-5 und Occludin, sowie ein stabilisierendes Expressionsverhalten der Transmembranproteine Integrin a 1 und Integrin a v nach Behandlung mit STVNA nachgewiesen. Ebenso wurde eine verminderte Expression des Glukosetransporters GLUT 1 beobachtet. Eine Volumenreduktion der cerebEND Zellen durch STVNA, während 4h OGD und gleichzeitiger Behandlung mit STVNA konnte ebenfalls festgestellt werden. Die Ergebnisse dieser Arbeit stützen die Thesen und Ergebnisse der aktuellen Literatur, dass STVNA neuroprotektive Eigenschaften hat. N2 - The endothelial cells of the BBB are acutely vital during ischemia due to hypoxia and hypoglycemia. A breakdown of the BBB's barrier function results in life-threatening complications and is a common cause of death. The aim of this work was to demonstrate a neuroprotective effect of STVNA on mouse cerebEND cells in an in vitro model of stroke. Mouse cerebEND cells were exposed to OGD for 4 h and then treated with 0, 1, 5, 10 and 20 mg/l STVNA for 4 h and 24 h. The respective cells were harvested directly, 4 h and 24 h after 4 h OGD and evaluated by Western Blot and qRT-PCR. An increased expression of the tight junction proteins Claudin-5 and Occludin as well as a stabilizing expression behavior of the transmembrane proteins integrin a1 and integrin av were detected after treatment with STVNA. A reduced expression of the glucose transporter GLUT 1 was also observed. A volume reduction of the cerebEND cells by STVNA, during 4h OGD and simultaneous treatment with STVNA could also be determined. The results of this work support the theses and results of the current literature that STVNA has neuroprotective properties. KW - Stevia rebaudiana KW - Schlaganfall KW - Isosteviol-Natrium Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-310606 ER - TY - THES A1 - Hackenbroich, Samantha T1 - Effekt der Inklusion von Abstraktpublikationen in die Netzwerk-Metaanalyse zur Prävention von postoperativer Übelkeit und Erbrechen und Analyse der Berichterstattungsqualität T1 - Effect of inclusion of abstract publications in the network meta-analysis on prevention of postoperative nausea and vomiting and assessment of reporting quality N2 - Systematische Übersichtsarbeiten und Metaanalysen zielen darauf ab, die gesamte verfügbare Evidenz zu einer Fragestellung zu erfassen. Die aktuelle Cochrane Netzwerk-Metaanalyse (NMA) verglich Antiemetika zur Prävention von postoperativer Übelkeit und Erbrechen. Die vorliegende Untersuchung ergänzte den Studienpool retrospektiv um die ursprünglich exkludierten Kongressabstracts und analysierte deren Mehrwert hinsichtlich Berichterstattungsqualität und Auswirkung auf die NMA. Kongressabstracts wurden bezüglich Studiencharakteristika, Biasrisiko und Berichter-stattung analysiert. Die Auswirkung des Einschlusses von Abstracts wurde mittels Sensitivitäts-Netzwerk-Metaanalysen analysiert. Anhand CONSORT (Consolidated Standards of Reporting Trials) für Abstracts wurde ein Beispielabstract verfasst. Von 90 identifizierten Abstracts waren 14 % (13/90) inkludierbar und bei 86 % (77/90) ist die Klassifikation im Hinblick auf Ein- oder Ausschlussfähigkeit aufgrund insuffizienter Berichterstattung der engen Einschlusskriterien der NMA ausstehend. Dabei fehlten bei 71 % (55/77) der Abstracts Informationen zur Standardisierung der Anästhesie, bei 56 % (43/77) zum Alter der Teilnehmer und bei 46 % (36/77) zu den Endpunktdetails. In 73 % (66/90) der Abstracts fehlten suffiziente Informationen zu 15 von 25 Datenextraktions-merkmalen. Die berichteten Studiencharakteristika der Abstracts waren vergleichbar mit den inkludierten Studien der NMA. 62 % (56/90) der Abstractstudien hatten aufgrund mangelhafter Berichterstattung ein hohes Gesamt-Biasrisiko. Die Adhärenz zu CONSORT für Abstracts betrug im Median 24 % (IQR: 18 % - 29 %). Eine Verbesserung der Berichterstattung nach der Publikation von CONSORT für Abstracts war nicht zu beobachten. Nur sechs der inkludierbaren Abstracts berichteten relevante Endpunktdaten suffizient und konnten in Sensitivitäts-NMAs inkludiert werden. Deren Inklusion führte weder zu einer relevanten Änderung der Netzwerkstruktur oder Effektschätzungen noch des Rankings der Wirksamkeit der Antiemetika bzw. der klinischen Konklusion. Eine Empfehlung für zukünftige Abstracts mit Vorlage entsprechend der Kriterien der Fachgesellschaften sowie CONSORT für Abstracts konnte entwickelt werden. Die Mehrheit der identifizierten Abstracts waren insuffizient berichtet und konnten daher nicht eingeschlossen werden. Kongressorganisatoren sollten ihre Autoren zur Umsetzung von CONSORT für Abstracts verpflichten. Die ressourcenintensive Einbeziehung von Abstracts brachte keinen relevanten Evidenzgewinn. Somit kann die Inklusion von Kongressabstracts in systematische Übersichtsarbeiten mit engen Inklusionskriterien und solider Volltext-Evidenzbasis nicht empfohlen werden. N2 - Systematic reviews attempt to gather all available evidence. The current Cochrane network meta-analysis (NMA) compared antiemetics for prevention of postoperative nausea and vomiting. Studies published as conference abstracts only were excluded. This study retrospectively aimed to include studies published as conference abstracts only assessing their added value regarding reporting quality and effect on the review. Conference abstracts were analysed regarding study characteristics, risk of bias and reporting quality. Sensitivity network meta-analyses were conducted to assess the effect of the inclusion of the abstracts on the review. Using CONSORT (Consolidated Standards of Reporting Trials) an example abstracts was created. Of 90 abstracts identified, 14% (13/90) were eligible and 86% (77/90) are awaiting classification due to insufficient reporting of the NMA's narrow eligibility criteria. Among these, 71% (55/77) lacked information on standardisation of anaesthesia, 56% (43/77) lacked information on participant age, and 46% (36/77) lacked information on endpoint details. Sufficient information was missing on 15 of 25 data extraction items in 73% (66/90) of abstracts. The reported study characteristics of the abstracts were comparable to the included studies in the NMA. 62% (56/90) of abstract studies were assessed as overall high risk of bias due to poor reporting. Median adherence to CONSORT for abstracts was 24% (IQR: 18 to 29%). There was no improvement in reporting after publication of CONSORT for abstracts. Only six of the eligible abstracts reported relevant outcome data in sufficient detail to be included in sensitivity NMAs. Inclusion of abstracts did not substantially alter network structure, network effect estimates, nor the ranking of treatments or the conclusion. A recommendation for future abstracts according to criteria of societies in anaesthesiology and CONSORT for abstracts was developed. Most abstracts identified were insufficiently reported and therefore could not be included in NMA. Conferences should oblige their authors to adhere to CONSORT for abstracts. Resource-intensive inclusion of abstracts did not yield relevant evidence gains. Thus, inclusion of conference abstracts in systematic reviews with narrow inclusion criteria and solid full-text evidence base cannot be recommended. KW - Berichterstattung KW - Systematische Übersichtsarbeit KW - postoperative Übelkeit KW - Erbrechen Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-321669 ER - TY - JOUR A1 - Salvador, Ellaine A1 - Köppl, Theresa A1 - Hörmann, Julia A1 - Schönhärl, Sebastian A1 - Bugaeva, Polina A1 - Kessler, Almuth F. A1 - Burek, Malgorzata A1 - Ernestus, Ralf-Ingo A1 - Löhr, Mario A1 - Hagemann, Carsten T1 - Tumor Treating Fields (TTFields) induce cell junction alterations in a human 3D in vitro model of the blood-brain barrier JF - Pharmaceutics N2 - In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies. KW - blood-brain barrier KW - Tumor-Treating Fields (TTFields) KW - CNS disorders KW - human brain microvascular endothelial cells (HBMVEC) KW - human cells KW - 3D in vitro model Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304830 SN - 1999-4923 VL - 15 IS - 1 ER - TY - JOUR A1 - Sitter, Magdalena A1 - Fröhlich, Corinna A1 - Kranke, Peter A1 - Markus, Christian A1 - Wöckel, Achim A1 - Rehn, Monika A1 - Bartmann, Catharina A1 - Frieauff, Eric A1 - Meybohm, Patrick A1 - Pecks, Ulrich A1 - Röder, Daniel T1 - ECMO-Therapie bei COVID-19-ARDS in der Schwangerschaft ermöglicht den Erhalt einer Schwangerschaft mit termingerechter Entbindung T1 - ECMO therapy for COVID-19 ARDS (Acute Respiratory Distress Syndrome) during pregnancy enables preservation of pregnancy and full-term delivery JF - Die Anaesthesiologie N2 - No abstract available. KW - ECMO-Therapie KW - COVID-19-ARDS KW - Schwangerschaft KW - ECMO therapy KW - COVID-19-ARDS KW - pregnancy Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-346762 VL - 72 IS - 3 ER - TY - THES A1 - Dümpert, Maximilian T1 - Die simultane Versorgung von Traumapatienten in einem Doppel-Ganzkörper-CT-Schockraum: Eine retrospektive Beobachtungsstudie am Universitätsklinikum Würzburg T1 - The simultaneous treatment of trauma patients in a dual-room whole-body CT trauma suite: A retrospective observational study at the university hospital Würzburg N2 - Hintergrund Die Versorgung Schwerverletzter setzt das zügige Erkennen lebensbedrohlicher Verletzungen und deren Priorisierung voraus. Hierzu verfügt das Universitätsklinikum Würzburg seit 2018 über ein Doppelschockraumkonzept mit Ganzkörper-CT, fahrbarer CT-Gantry und einer mobilen Schutzwand, wodurch zwei Personen nahezu simultan behandelt werden können. Das Ziel der vorliegenden Arbeit war zum Einen mögliche Spezifika von simultan versorgten Patienten und Patientinnen zu identifizieren und zum Anderen die Evaluation möglicher Unterschiede in der Qualität der Versorgung in einem Doppel- und einem Einzelschockraum, insbesondere der Zeit bis zur CT-Bildgebung und bis zum Beginn operativer Maßnahmen. Methodik Im Rahmen einer retrospektiven Untersuchung wurden die Patientendaten aller Schockraumaufnahmen des Universitätsklinikums Würzburg vom 1. Mai 2019 bis zum 29. April 2020 analysiert. Die Datensätze wurden bei einer simultanen Versorgung im Schockraum der Doppelschockraumgruppe (Gruppe 1) und bei einer alleinigen Versorgung der Einzelschockraumgruppe (Gruppe 2) zugeordnet. Ergebnisse 10,9 % aller Schockraumaufnahmen wurden simultan im Schockraum versorgt (46 von 423). Personen aus Gruppe 1 verunglückten häufiger bei PKW-Unfällen (47,8 % vs. 19,6 %; p < 0,05). Keine Unterschiede fanden sich bezüglich Alter, Geschlecht, ASA, ISS und präklinischer Versorgung. Die Klinik bei der Aufnahme unterschied sich nicht bezüglich A-, B-, C- und D-Problemen, allerdings litten Personen aus Gruppe 1 häufiger unter Schmerzen (hier als E-Problem nach ATLS klassifiziert) (45,7 % vs. 29,2 %; p < 0,05). Die Versorgung im Schockraum (Instrumentierung, Medikamentenapplikation, Transfusion) ergab keine relevanten Unterschiede. Insbesondere zeigte sich keine klinisch relevante Verzögerung bei simultan versorgten Patienten und Patientinnen bis zur CT-Bildgebung oder dem Beginn operativer Maßnahmen (tCT: 8 vs. 6 min (Gruppe 1 vs. Gruppe 2), p < 0,05; tOP: 99 vs. 90 min (Gruppe 1 vs. Gruppe 2), p < 0,05). Auch das Outcome in beiden Gruppen war vergleichbar. Diskussion Die simultane Versorgung zweier Schwerverletzter stellt hohe Anforderungen an Personal, Ausstattung und Organisation. Das in dieser Arbeit untersuchte Doppelschockraumkonzept kann auch bei simultan versorgten Patienten und Patientinnen eine bestmögliche Versorgung auf individualmedizinischem Niveau gewährleistet werden. N2 - Background The treatment of seriously injured patients requires a fast diagnosis of life-threatening injuries and their prioritization. Therefore, the university hospital Würzburg has a dual-room trauma suite concept with whole-body CT, a movable CT gantry and a mobile X-ray protection wall since 2018, which allows the simultaneous treatment of two patients. The aim of the present study was to identify the specifics of simultaneously treated patients and to evaluate differences in the quality of treatment between a dual and a single trauma suit treatment, especially in the time until CT diagnosis and the time until the beginning of surgical procedures. Methods The data of all trauma suite administrations between January 5, 2019 and April 29, 2020 was analyzed as an observational study. The data were assigned to a dual trauma suite treatment group (group 1) if two patients were treated simultaneously and to a single trauma suite group (group 2) if patients were treated solo. Results 10.9 % of all trauma room administrations were treated simultaneously (46 out of 423). There were more car accidents in patients in group 1 (47.8 % vs. 19.6 %; p< 0.05). There were no differences in age, sex, ASA, ISS and preclinical treatment. There were no differences in the clinical status at the administration regarding A-, B-, C- and D-problems, but patients in group 1 suffered more often from pain (classified as an E-problem) (45.7 % vs. 29.2 %; p < 0.05). There were no differences in the treatment in the trauma suite (catheters, medication or transfusion). There was no clinically relevant delay until the CT diagnosis and the beginning of surgical procedures. (tCT: 8 vs. 6 min) (group 1 vs. group 2), p < 0.05; tOR: 99 min vs. 90 min (group 1 vs. group 2; p < 0.05). The outcome in both groups was comparable. Discussion The simultaneous treatment of two seriously injured patients makes high demands on personnel, equipment and organization. The examined dual trauma suite concept may ensure the best possible treatment at the highest standards for single-treated patients as well as for simultaneously treated ones. KW - Schockraummanagement KW - Notfallmedizin KW - Traumatologie KW - Schockraumbehandlung KW - Doppel-Ganzkörper-CT-Schockraum Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-345213 ER - TY - JOUR A1 - Löb, Sanja A1 - Linsmeier, Eva A1 - Herbert, Saskia-Laureen A1 - Schlaiß, Tanja A1 - Kiesel, Matthias A1 - Wischhusen, Jörg A1 - Salmen, Jessica A1 - Kranke, Peter A1 - Quenzer, Anne A1 - Kurz, Florian A1 - Weiss, Claire A1 - Gerhard-Hartmann, Elena A1 - Wöckel, Achim A1 - Diessner, Joachim T1 - Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases JF - Journal of Cancer Research and Clinical Oncology N2 - Purpose Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease. Methods This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated. Results In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p < 0.000). In the cohort of the first relapse, HER2-low represented 64.1% of HR-positive vs. 48.2% of the triple-negative cohort (p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion. Conclusion HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important. KW - breast cancer KW - HER2 conversion KW - HER2-low KW - trastuzumab deruxtecan KW - HER2 targeted therapy KW - trastuzumab Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324068 VL - 149 IS - 8 ER - TY - THES A1 - Mayer, Debora T1 - Untersuchung des Publikationsbias im Rahmen des Cochrane-Reviews „Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis“ T1 - Examination of publication bias in the Cochrane-Review „Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis“ N2 - PONV ist eine häufige und für Patient*innen belastende Nebenwirkung nach einer Allgemeinanästhesie. Trotz der Vielzahl an Studien zu den zahlreichen antiemetischen Medikamenten gibt es bisher keinen Überblick über die Effizienz und Sicherheit all dieser Medikamente. Im Rahmen des Cochrane-Reviews „Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis“ wurden RCTs zur Prävention von PONV nach Allgemeinanästhesie bei Erwachsenen gesucht. Zu den primären Endpunkten gehörten Erbrechen 0-24 Stunden, schwere unerwünschte Ereignisse und unerwünschte Ereignisse, zu den sekundären Endpunkten Substanz-spezifische Nebenwirkungen, frühes und spätes postoperatives Erbrechen, Übelkeit und vollständiger Behandlungserfolg. In dieser Dissertation wurden die Vergleiche mit mindestens zehn Studien auf das Vorliegen eines Publikationsbias überprüft. Die Beurteilung des Publikationsbias erfolgte unter Anwendung verschiedener Tests (Funnel Plots, contour-enhanced Funnel Plot, Arcsine Test, Trim-and-Fill-Methode). Bei sieben von den 64 analysierten Vergleichen wurde der Verdacht auf einen Publikationsbias gestellt. Für den primären Endpunkt Erbrechen 0-24 Stunden wurde bei zwei Vergleichen (Droperidol vs. Placebo und Metoclopramid vs. Ondansetron) ein Publikationsbias vermutet, für die sekundären Endpunkte Übelkeit bei drei Vergleichen (Tropisetron vs. Placebo, Dexamethason-Ondansetron vs. Dexamethason, Dexamethason-Ondansetron vs. Ondansetron) und für den vollständigen Behandlungserfolg bei zwei Vergleichen (Droperidol vs. Placebo, Ondansetron vs. Placebo). Die Effektschätzer der restlichen 54 Vergleiche sind hinsichtlich der klinischen Relevanz robust und eine Verzerrung durch einen Publikationsbias wurde nicht vermutet. N2 - PONV is a common adverse event after general anaesthesia with a high impact on patients satisfaction in the postoperative period. There are many antiemetic drugs and a lot of trials on this topic, but there is no comparative ranking of efficiency and safety of all these drugs. This is the aim of the Cochrane-Review „Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta- analysis“. We searched for RCTs comparing the effectiveness and safety of antiemetic drugs. Primary outcomes were vomiting 0-24 hours, severe adverse events and any adverse events. Secondary outcomes were drug class-specific side effects, mortality, early and late vomiting, nausea, and complete response. In this dissertation publication bias was explored in pairwise meta-analysis of comparisons with at least 10 RCTs using different tests (funnel plots, contour-enhanced funnel plots, arcsine test and trim and fill sensitivity analysis). Publication bias was assessed in 64 comparisons. In seven comparisons publication bias was suspected. For the primary outcome vomiting 0-24 hours, there were two comparisons with suspected publication bias (droperidol to placebo and metoclopramide to ondansetrone). For secondary outcomes nausea and complete response, there were three comparisons (tropisetrone to placebo, dexamethasone-ondansetrone to dexamethasone, dexamethasone-ondansetrone to ondansetrone) and two comparisons respectively (droperidol-placebo, ondansetrone- placebo) with suspected publication bias. The effects of these seven comparisons are overestimated and the evidence for an effect is unreliable. For the other 54 comparisons publication bias was not suspected. KW - Publikationsbias KW - publication bias KW - Übelkeit KW - Erbrechen KW - Cochrane Review KW - PONV KW - Nausea KW - Vomiting KW - postoperative Nausea Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-345070 ER - TY - THES A1 - Gegg, Tanja Susanne T1 - In Vitro Toxizität der Nanopartikel Graphen und Siliciumdioxid für die Medikamentenapplikation T1 - In vitro toxicity of the nanoparticles Graphene and Silicon dioxide for drug targeting N2 - Graphen und Siliciumdioxid Nanopartikel sind als Trägersubstanz für Medikamente beim Drug Targeting von Interesse. Diese Arbeit ist eine toxikologische Untersuchung der Nanopartikel Graphen und Siliciumdioxid im Zellmodell. Dabei wurden Graphen Nanopartikel mit einer Dicke von 6 bis 8 nm und einer Breite von 15 µm verwendet. Die verwendeten Siliciumdioxid Nanopartikel waren kugelförmig und porös mit einer Partikel-Größe von 5 bis 20 nm. Die dosisabhängige Toxizität (Konzentrationen 0,01 mg/ml, 0,1 mg/ml und 1 mg/ml, Inkubation über 24 Stunden) gegenüber 5 verschiedenen Zelllinien (cerebEND, Caco-2, Hep G2, HEK-293, H441) wurde geprüft. Dabei kamen Zellviabilitätstests (CellTiter-Glo Assay, EZ4U-Test) zum Einsatz. Zudem wurde mit den Apoptose-Markern Bax und Caspase-3 auf Gen- und Proteinebene (Polymerasekettenreaktion und Western Blot) überprüft, ob eine Apoptose eingeleitet wurde. Zur Untersuchung der Zellviabilität wurde der CellTiter-Glo Assay verwendet. Für Graphen Nanopartikel zeigte sich ab einer Konzentration von 1 mg/ml bei den Zelllinien HEK-293 und H441 ein statistisch signifikanter Abfall der Zellviabilität. CerebEND und Hep G2 Zellen reagierten auf Graphen Nanopartikel ab einer Konzentration von 1 mg/ml ebenfalls mit einem deutlichen Abfall der Zellviabilität, diese Ergebnisse waren jedoch nicht statistisch signifikant. Die Zelllinie Caco-2 zeigte sich von den Graphen Nanopartikeln unbeeindruckt, es kam zu keiner statistisch signifikanten Veränderung der Zellviabilität. Siliciumdioxid Nanopartikel bewirkten ab einer Konzentration von 1 mg/ml einen statistisch signifikanten Abfall der Zellviabilität bei den Zelllinien cerebEND, HEK-293 und H441. HepG2 Zellen zeigten bei 1 mg/ml Siliciumdioxid einen deutlichen aber statistisch nicht signifikanten Abfall der Zellviabilität. Die Zelllinie Caco-2 erwies sich auch bei Siliciumdioxid Nanopartikel als äußerst robust und zeigte keine statistisch signifikanten Veränderungen der Zellviabilität. Messungen der Zellviabilität auf Grundlage von Adsorptionsmessung, wie beim EZ4U-Test, hatten sich als ungeeignet erwiesen, da die Eigenfarbe der Nanopartikel Graphen und Siliciumdioxid mit dieser Messung interferierte. Zudem wurde geprüft, ob die bei einem Teil der Zelllinien eingetretene toxische Wirkung der Nanopartikel ab einer Konzentration von 1 mg/ml durch Nekrose oder durch Apoptose zustande kam. Die Polymerasekettenreaktion zeigte mit einer einzigen Ausnahme keine statistisch signifikante Erhöhung der Genexpression für Bax und Caspase-3 und gab somit auch keine Hinweise auf die Einleitung einer Apoptose. Im Western Blot zeigte sich keine statistisch signifikante Erhöhung der Proteinexpression von Bax und Caspase-3. Zudem konnte im Western Blot auch keine aktivierte Caspase-3 nachgewiesen werden. Somit lagen auf Grundlage von Polymerasekettenreaktion und Western Blot keine Hinweise auf das Eintreten einer Apoptose vor. Die toxische Wirkung der Nanopartikel Graphen und Siliciumdioxid, die bei einem Teil der Zelllinien ab einer Konzentration von 1 mg/ml nachgewiesen werden konnte, beruhte demnach auf Nekrose. N2 - Graphene and silicon dioxide nanoparticles are of interest as drug carriers for controlled drug delivery systems. This thesis is an evaluation of the toxic properties of the nanoparticles Graphene and Silicon dioxide based on tests on cell culture. The Graphene nanoplatelets were 6 to 8 nm thick and 15 µm wide. The Silicon dioxide nanoparticles were spherical and porous with a particle size of 5 to 20 nm. The dose dependent toxicity (concentrations 0,01 mg/ml, 0,1 mg/ml und 1 mg/ml, incubation over 24 hours) was tested on 5 different cell lines (cerebEND, Caco-2, Hep G2, HEK-293, H441). I used cell viability test (CellTiter-Glo Assay, EZ4U-test). In addition, I used PCR (Polymerase chain reaction) and western blot to detect the apoptosis markers Bax and Caspase-3, to see if the nanoparticles cause an apoptosis or a necrosis. For investigating the cell viability, I used the CellTiter-Glo Assay. Graphene nanoplatelets showed from a concentration of 1 mg/ml for the cell lines HEK-293 und H441 a statistically significant decrease of cell viability. CerebEND and Hep G2 cells reacted on Graphene nanoplatelets from a concentration of 1 mg/ml with a clearly decrease in cell viability, but these results were not statistically significant. The cell line Coco-2 showed no decrease in cell viability after the incubation with Graphene nanoplatelets. Silicon dioxide nanoparticles showed from a concentration of 1 mg/ml a statistic significant decrease of cell viability in the cell lines cerebEND, HEK-293 and H441. The Hep G2 cells showed a decrease in cell viability as well, but the results were not statistically significant. The cell line Caco-2 showed no decrease in cell viability after the incubation with Silicon dioxide nanoparticles. Cell viability tests based on the messurement of adsorption like the EZ4U-test, proved not suitable for this setting, because the own color of the nanoparticles interfered with the measurement. In addition, I tested if the nanoparticles caused an apoptosis or a necrosis. The PCR showed with one exception no statistically significant increase in the gene expression of Bax and Caspase-3 and therefore no proof of apoptosis. The western blot showed no statistically significant increase in the protein expression of Bax and Caspase-3. And it detected no activated Caspase-3. There was based on PCR and western blot no sign for the cells to enter in apoptosis. The toxic properties of the nanoparticles Graphene and Silicon dioxide, that was shown in a part of the cell lines from a concentration of 1 mg/ml, was therefore based on necrosis. KW - Nanopartikel KW - Toxizität KW - Graphen KW - Siliciumdioxid KW - Drug Targeting KW - Targeted drug delivery KW - Zellkultur Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-330562 ER - TY - THES A1 - Sun, Aili T1 - Effect of Tjap1 knock-down on blood-brain barrier properties under normal and hypoxic conditions T1 - Auswirkung des Tjap1-Knockdowns auf die Eigenschaften der Blut-Hirn-Schranke unter normalen und hypoxischen Bedingungen N2 - Stroke is one of the leading causes of mortality and disability worldwide. The blood-brain barrier (BBB) plays an important role in maintaining brain homeostasis by tightly regulating the exchange of substances between circulating blood and brain parenchyma. BBB disruption is a common pathologic feature of stroke and traumatic brain injury. Understanding the cellular and molecular events that affect the BBB after ischaemic brain injury is important to improve patient prognosis. We have previously shown that microRNA-212/132 is elevated in hypoxic brain microvascular endothelial cells and acts through suppressing the expression of direct microRNA-212/132 target genes with function at the BBB: claudin-1, junctional adhesion molecule 3 (Jam3) and tight-junction associated protein 1 (Tjap1). While the role of claudin-1 and Jam3 at the BBB is well known, the role of Tjap1 is still unclear. The aim of this work was therefore to characterize the role of Tjap1 in brain endothelial cells using a knock-down (KD) approach in established murine in vitro BBB models cEND and cerebEND. Tjap1 KD was established by stable transfection of a plasmid expressing shRNA against Tjap1. The successful downregulation of Tjap1 mRNA and protein was demonstrated by qPCR and Western blot. Tjap1 KD resulted in impaired barrier properties of endothelial cells as shown by lower TEER values and higher paracellular permeability. Interestingly, the Tjap1 KD cells showed lower cell viability and proliferation but migrated faster in a wound healing assay. In the tube formation assay, Tjap1 KD cell lines showed a lower angiogenic potential due to a significantly lower tube length and number as well as a lower amount of branching points in formed capillaries. Tjap1 KD cells showed changes in gene and protein expression. The TJ proteins claudin-5, Jam3 and ZO-1 were significantly increased in Tjap1 KD cell lines, while occludin was strongly decreased. In addition, efflux pump P-glycoprotein was downregulated in Tjap1 KD cells. Oxygen-glucose deprivation (OGD) is a method to mimic stroke in vitro. Brain endothelial cell lines treated with OGD showed lower barrier properties compared to cells cultured under normal condition. These effects were more severe in Tjap1 KD cells, indicating active Tjap1 involvement in the OGD response in brain microvascular endothelial cells. We thus have shown that Tjap1 contributes to a tight barrier of the BBB, regulates cell viability and proliferation of endothelial cells, suppresses their migration and promotes new vessel formation. This means that Tjap1 function is important for mature BBB structure in health and disease. N2 - Schlaganfall ist weltweit eine der häufigsten Ursachen für Mortalität und Behinderung. Die Blut-Hirn-Schranke (BHS) spielt eine wichtige Rolle bei der Aufrechterhaltung der Gehirnhomöostase, indem sie den Stoffaustausch zwischen dem zirkulierenden Blut und dem Gehirnparenchym streng reguliert. Eine Störung der BHS ist ein gemeinsames pathologisches Merkmal von Schlaganfällen und traumatischen Hirnverletzungen. Um die Prognose der Patientinnen und Patienten zu verbessern, ist es wichtig, die zellulären und molekularen Ereignisse zu verstehen, die sich nach einer ischämischen Hirnverletzung auf die BHS auswirken. Wir haben zuvor gezeigt, dass microRNA-212/132 in hypoxischen mikrovaskulären Endothelzellen erhöht ist und durch die Unterdrückung der Expression direkter Zielgene mit Funktion and der BHS wirkt. Zu den Zielgenen von microRNA-212/132 gehören: Claudin-1, Junctional Adhesion Molecule 3 (Jam3) und Tight Junction Associated Protein 1 (Tjap1). Während die Rolle von Caludin-1 und Jam3 and der BHS gut bekannt ist, ist die Rolle von Tjap1 noch unklar. Ziel dieser Arbeit war es daher, die Rolle von Tjap1 in Endothelzellen mithilfe eines Knock-down (KD)-Ansatzes in etablierten murinen In-vitro-BHS-Modellen zu charakterisieren. Tjap1-KD wurde durch stabile Transfektion eines Plasmids etabliert, das shRNA gegen Tjap1 exprimiert. Die erfolgreiche Herunterregulierung von Tjap1-mRNA und -Protein wurde durch qPCR und Western Blot nachgewiesen. Tjap1-KD führte zu einer Beeinträchtigung der Barriereeigenschaften von Endothelzellen, was sich in niedrigeren TEER-Werten und einer höheren parazellulären Permeabilität wiederspiegelte. Interessanterweise zeigten die Tjap1-KD-Zellen in einem Wundheilungstest eine geringere Zelllebensfähigkeit und Proliferation, wanderten jedoch schneller. Im tube formation assay zeigten Tjap1-KD-Zelllinien ein geringeres Angiogenese-Potential durch eine signifikant geringere Anzahl der gebildeten Kapillaren. Tjap-1-KD-Zellen zeigten Veränderungen in der Gen- und Proteinexpression. Die TJ-Proteinen Claudin-5, Jam3 und ZO-1 waren in Tjap1-KD-Zelllinien signifikant erhöht, während Occludin stark verringert war. Darüber hinaus wurde P-Glykoprotein in Tjap1-KD-Zellen herunterreguliert. Sauerstoff-Glukose-Entzug (eng. oxygen/glucose-deprivation, OGD) ist eine Methode zur Nachahmung eines Schlaganfall in vitro. Mit OGD behandelte Endothelzelllinien zeigten im Vergleich zu unter normalen Bedingungen kultivierten Zellen geringere Barriereeigenschaften. Diese Effekte waren in Tjap1-KD-Zellen schwerwiegender, was auf eine aktive Beteiligung von Tjap1 an der OGD-Antwort in Endothelzellen hinweist. Wir haben gezeigt, dass Tjap1 zu einer dichten Barriere der BHS beiträgt, die Zellviabilität und die Proliferation von Endothelzellen reguliert, deren Migration unterdrückt und die Bildung neuer Gefäße fördert. Dies bedeutet, dass die Tjap1-Funktion für die reife BHS-Struktur unter physiologischen und pathophysiologischen Bedingungen wichtig ist. KW - Schlaganfall KW - Blut-Hirn-Schranke KW - blood-brain barrier KW - Tjap1 KW - oxygen/glucose deprivation KW - stroke Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-346450 ER - TY - JOUR A1 - Henckert, David A1 - Malorgio, Amos A1 - Schweiger, Giovanna A1 - Raimann, Florian J. A1 - Piekarski, Florian A1 - Zacharowski, Kai A1 - Hottenrott, Sebastian A1 - Meybohm, Patrick A1 - Tscholl, David W. A1 - Spahn, Donat R. A1 - Roche, Tadzio R. T1 - Attitudes of anesthesiologists toward artificial intelligence in anesthesia: a multicenter, mixed qualitative–quantitative study JF - Journal of Clinical Medicine N2 - Artificial intelligence (AI) is predicted to play an increasingly important role in perioperative medicine in the very near future. However, little is known about what anesthesiologists know and think about AI in this context. This is important because the successful introduction of new technologies depends on the understanding and cooperation of end users. We sought to investigate how much anesthesiologists know about AI and what they think about the introduction of AI-based technologies into the clinical setting. In order to better understand what anesthesiologists think of AI, we recruited 21 anesthesiologists from 2 university hospitals for face-to-face structured interviews. The interview transcripts were subdivided sentence-by-sentence into discrete statements, and statements were then grouped into key themes. Subsequently, a survey of closed questions based on these themes was sent to 70 anesthesiologists from 3 university hospitals for rating. In the interviews, the base level of knowledge of AI was good at 86 of 90 statements (96%), although awareness of the potential applications of AI in anesthesia was poor at only 7 of 42 statements (17%). Regarding the implementation of AI in anesthesia, statements were split roughly evenly between pros (46 of 105, 44%) and cons (59 of 105, 56%). Interviewees considered that AI could usefully be used in diverse tasks such as risk stratification, the prediction of vital sign changes, or as a treatment guide. The validity of these themes was probed in a follow-up survey of 70 anesthesiologists with a response rate of 70%, which confirmed an overall positive view of AI in this group. Anesthesiologists hold a range of opinions, both positive and negative, regarding the application of AI in their field of work. Survey-based studies do not always uncover the full breadth of nuance of opinion amongst clinicians. Engagement with specific concerns, both technical and ethical, will prove important as this technology moves from research to the clinic. KW - artificial intelligence KW - machine learning KW - anesthesia KW - anesthesiology KW - qualitative research KW - clinical decision support Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-311189 SN - 2077-0383 VL - 12 IS - 6 ER - TY - JOUR A1 - Schweiger, Giovanna A1 - Malorgio, Amos A1 - Henckert, David A1 - Braun, Julia A1 - Meybohm, Patrick A1 - Hottenrott, Sebastian A1 - Froehlich, Corinna A1 - Zacharowski, Kai A1 - Raimann, Florian J. A1 - Piekarski, Florian A1 - Noethiger, Christoph B. A1 - Spahn, Donat R. A1 - Tscholl, David W. A1 - Roche, Tadzio R. T1 - Visual Blood, a 3D animated computer model to optimize the interpretation of blood gas analysis JF - Bioengineering N2 - Acid–base homeostasis is crucial for all physiological processes in the body and is evaluated using arterial blood gas (ABG) analysis. Screens or printouts of ABG results require the interpretation of many textual elements and numbers, which may delay intuitive comprehension. To optimise the presentation of the results for the specific strengths of human perception, we developed Visual Blood, an animated virtual model of ABG results. In this study, we compared its performance with a conventional result printout. Seventy physicians from three European university hospitals participated in a computer-based simulation study. Initially, after an educational video, we tested the participants’ ability to assign individual Visual Blood visualisations to their corresponding ABG parameters. As the primary outcome, we tested caregivers’ ability to correctly diagnose simulated clinical ABG scenarios with Visual Blood or conventional ABG printouts. For user feedback, participants rated their agreement with statements at the end of the study. Physicians correctly assigned 90% of the individual Visual Blood visualisations. Regarding the primary outcome, the participants made the correct diagnosis 86% of the time when using Visual Blood, compared to 68% when using the conventional ABG printout. A mixed logistic regression model showed an odds ratio for correct diagnosis of 3.4 (95%CI 2.00–5.79, p < 0.001) and an odds ratio for perceived diagnostic confidence of 1.88 (95%CI 1.67–2.11, p < 0.001) in favour of Visual Blood. A linear mixed model showed a coefficient for perceived workload of −3.2 (95%CI −3.77 to −2.64) in favour of Visual Blood. Fifty-one of seventy (73%) participants agreed or strongly agreed that Visual Blood was easy to use, and fifty-five of seventy (79%) agreed that it was fun to use. In conclusion, Visual Blood improved physicians’ ability to diagnose ABG results. It also increased perceived diagnostic confidence and reduced perceived workload. This study adds to the growing body of research showing that decision-support tools developed around human cognitive abilities can streamline caregivers’ decision-making and may improve patient care. KW - blood gas analysis KW - medical devices KW - point-of-care-testing KW - situational awareness KW - technology Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304150 SN - 2306-5354 VL - 10 IS - 3 ER - TY - JOUR A1 - Bergauer, Lisa A1 - Akbas, Samira A1 - Braun, Julia A1 - Ganter, Michael T. A1 - Meybohm, Patrick A1 - Hottenrott, Sebastian A1 - Zacharowski, Kai A1 - Raimann, Florian J. A1 - Rivas, Eva A1 - López-Baamonde, Manuel A1 - Spahn, Donat R. A1 - Noethiger, Christoph B. A1 - Tscholl, David W. A1 - Roche, Tadzio R. T1 - Visual Blood, visualisation of blood gas analysis in virtual reality, leads to more correct diagnoses: a computer-based, multicentre, simulation study JF - Bioengineering N2 - Interpreting blood gas analysis results can be challenging for the clinician, especially in stressful situations under time pressure. To foster fast and correct interpretation of blood gas results, we developed Visual Blood. This computer-based, multicentre, noninferiority study compared Visual Blood and conventional arterial blood gas (ABG) printouts. We presented six scenarios to anaesthesiologists, once with Visual Blood and once with the conventional ABG printout. The primary outcome was ABG parameter perception. The secondary outcomes included correct clinical diagnoses, perceived diagnostic confidence, and perceived workload. To analyse the results, we used mixed models and matched odds ratios. Analysing 300 within-subject cases, we showed noninferiority of Visual Blood compared to ABG printouts concerning the rate of correctly perceived ABG parameters (rate ratio, 0.96; 95% CI, 0.92–1.00; p = 0.06). Additionally, the study revealed two times higher odds of making the correct clinical diagnosis using Visual Blood (OR, 2.16; 95% CI, 1.42–3.29; p < 0.001) than using ABG printouts. There was no or, respectively, weak evidence for a difference in diagnostic confidence (OR, 0.84; 95% CI, 0.58–1.21; p = 0.34) and perceived workload (Coefficient, 2.44; 95% CI, −0.09–4.98; p = 0.06). This study showed that participants did not perceive the ABG parameters better, but using Visual Blood resulted in more correct clinical diagnoses than using conventional ABG printouts. This suggests that Visual Blood allows for a higher level of situation awareness beyond individual parameters’ perception. However, the study also highlighted the limitations of today’s virtual reality headsets and Visual Blood. KW - virtual reality KW - blood gas analysis KW - data display KW - point-of-care KW - situation awareness KW - user-centred design KW - diagnostic correctness Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-310979 SN - 2306-5354 VL - 10 IS - 3 ER - TY - JOUR A1 - Wilhelms, Benedikt A1 - Broscheit, Jens A1 - Shityakov, Sergey T1 - Chemical analysis and molecular modelling of cyclodextrin-formulated propofol and its sodium salt to improve drug solubility, stability and pharmacokinetics (cytogenotoxicity) JF - Pharmaceuticals N2 - Propofol is a widely used general anesthetic in clinical practice, but its use is limited by its water-insoluble nature and associated pharmacokinetic and pharmacodynamic limitations. Therefore, researchers have been searching for alternative formulations to lipid emulsion to address the remaining side effects. In this study, novel formulations for propofol and its sodium salt Na-propofolat were designed and tested using the amphiphilic cyclodextrin (CD) derivative hydroxypropyl-β-cyclodextrin (HPβCD). The study found that spectroscopic and calorimetric measurements suggested complex formation between propofol/Na-propofolate and HPβCD, which was confirmed by the absence of an evaporation peak and different glass transition temperatures. Moreover, the formulated compounds showed no cytotoxicity and genotoxicity compared to the reference. The molecular modeling simulations based on molecular docking predicted a higher affinity for propofol/HPβCD than for Na-propofolate/HPβCD, as the former complex was more stable. This finding was further confirmed by high-performance liquid chromatography. In conclusion, the CD-based formulations of propofol and its sodium salt may be a promising option and a plausible alternative to conventional lipid emulsions. KW - propofol KW - anaesthesiology KW - HPβCD KW - \(^1\)H-NMR spectroscopy KW - calorimetry KW - molecular modelling KW - cytotoxicity KW - genotoxicity Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-313705 SN - 1424-8247 VL - 16 IS - 5 ER - TY - JOUR A1 - Holzmann-Littig, Christopher A1 - Stadler, David A1 - Popp, Maria A1 - Kranke, Peter A1 - Fichtner, Falk A1 - Schmaderer, Christoph A1 - Renders, Lutz A1 - Braunisch, Matthias Christoph A1 - Assali, Tarek A1 - Platen, Louise A1 - Wijnen-Meijer, Marjo A1 - Lühnen, Julia A1 - Steckelberg, Anke A1 - Pfadenhauer, Lisa A1 - Haller, Bernhard A1 - Fuetterer, Cornelia A1 - Seeber, Christian A1 - Schaaf, Christian T1 - Locating medical information during an infodemic: information seeking behavior and strategies of health-care workers in Germany JF - Healthcare N2 - Background: The COVID-19 pandemic has led to a flood of — often contradictory — evidence. HCWs had to develop strategies to locate information that supported their work. We investigated the information-seeking of different HCW groups in Germany. Methods: In December 2020, we conducted online surveys on COVID-19 information sources, strategies, assigned trustworthiness, and barriers — and in February 2021, on COVID-19 vaccination information sources. Results were analyzed descriptively; group comparisons were performed using χ\(^2\)-tests. Results: For general COVID-19-related medical information (413 participants), non-physicians most often selected official websites (57%), TV (57%), and e-mail/newsletters (46%) as preferred information sources — physicians chose official websites (63%), e-mail/newsletters (56%), and professional journals (55%). Non-physician HCWs used Facebook/YouTube more frequently. The main barriers were insufficient time and access issues. Non-physicians chose abstracts (66%), videos (45%), and webinars (40%) as preferred information strategy; physicians: overviews with algorithms (66%), abstracts (62%), webinars (48%). Information seeking on COVID-19 vaccination (2700 participants) was quite similar, however, with newspapers being more often used by non-physicians (63%) vs. physician HCWs (70%). Conclusion: Non-physician HCWs more often consulted public information sources. Employers/institutions should ensure the supply of professional, targeted COVID-19 information for different HCW groups. KW - COVID-19 KW - infodemic KW - health-care workers KW - HCW KW - information strategies KW - emergency information Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-319306 SN - 2227-9032 VL - 11 IS - 11 ER - TY - JOUR A1 - Sammeth, Michael A1 - Ursache, Nicu-Cosmin A1 - Alboaie, Sînică T1 - OpenDSU: digital sovereignty in PharmaLedger JF - Frontiers in Blockchain N2 - Introduction: Distributed ledger networks, chiefly those based on blockchain technologies, currently are heralding a next-generation of computer systems that aims to suit modern users’ demands. Over the recent years, several technologies for blockchains, off-chaining strategies, as well as decentralised and respectively self-sovereign identity systems have shot up so fast that standardisation of the protocols is lagging behind, severely hampering the interoperability of different approaches. Moreover, most of the currently available solutions for distributed ledgers focus on either home users or enterprise use case scenarios, failing to provide integrative solutions addressing the needs of both. Methods: Herein, we introduce the OpenDSU platform that allows to interoperate generic blockchain technologies, organised–and possibly cascaded in a hierarchical fashion–in domains. To achieve this flexibility, we seamlessly integrated a set of well conceived components that orchestrate off-chain data and provide granularly resolved and cryptographically secure access levels, intrinsically nested with sovereign identities across the different domains. The source code and extensive documentation of all OpenDSU components described herein are publicly available under the MIT open-source licence at https://opendsu.com. Results: Employing our platform to PharmaLedger, an inter-European network for the standardisation of data handling in the pharmaceutical industry and in healthcare, we demonstrate that OpenDSU can cope with generic demands of heterogeneous use cases in both, performance and handling substantially different business policies. Discussion: Importantly, whereas available solutions commonly require a predefined and fixed set of components, no such vendor lock-in restrictions on the blockchain technology or identity system exist in OpenDSU, making systems built on it flexibly adaptable to new standards evolving in the future. KW - opendsu KW - blockchain interoperability KW - off-chain data KW - blockchain anchoring KW - self-sovereign identities KW - pharmaledger KW - blockchain in healthcare KW - blockchain in the pharmaceutical industry Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-320458 SN - 2624-7852 VL - 6 ER - TY - JOUR A1 - Herrmann, Johannes A1 - Müller, Kerstin A1 - Notz, Quirin A1 - Hübsch, Martha A1 - Haas, Kirsten A1 - Horn, Anna A1 - Schmidt, Julia A1 - Heuschmann, Peter A1 - Maschmann, Jens A1 - Frosch, Matthias A1 - Deckert, Jürgen A1 - Einsele, Hermann A1 - Ertl, Georg A1 - Frantz, Stefan A1 - Meybohm, Patrick A1 - Lotz, Christopher T1 - Prospective single-center study of health-related quality of life after COVID-19 in ICU and non-ICU patients JF - Scientific Reports N2 - Long-term sequelae in hospitalized Coronavirus Disease 2019 (COVID-19) patients may result in limited quality of life. The current study aimed to determine health-related quality of life (HRQoL) after COVID-19 hospitalization in non-intensive care unit (ICU) and ICU patients. This is a single-center study at the University Hospital of Wuerzburg, Germany. Patients eligible were hospitalized with COVID-19 between March 2020 and December 2020. Patients were interviewed 3 and 12 months after hospital discharge. Questionnaires included the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), patient health questionnaire-9 (PHQ-9), the generalized anxiety disorder 7 scale (GAD-7), FACIT fatigue scale, perceived stress scale (PSS-10) and posttraumatic symptom scale 10 (PTSS-10). 85 patients were included in the study. The EQ5D-5L-Index significantly differed between non-ICU (0.78 ± 0.33 and 0.84 ± 0.23) and ICU (0.71 ± 0.27; 0.74 ± 0.2) patients after 3- and 12-months. Of non-ICU 87% and 80% of ICU survivors lived at home without support after 12 months. One-third of ICU and half of the non-ICU patients returned to work. A higher percentage of ICU patients was limited in their activities of daily living compared to non-ICU patients. Depression and fatigue were present in one fifth of the ICU patients. Stress levels remained high with only 24% of non-ICU and 3% of ICU patients (p = 0.0186) having low perceived stress. Posttraumatic symptoms were present in 5% of non-ICU and 10% of ICU patients. HRQoL is limited in COVID-19 ICU patients 3- and 12-months post COVID-19 hospitalization, with significantly less improvement at 12-months compared to non-ICU patients. Mental disorders were common highlighting the complexity of post-COVID-19 symptoms as well as the necessity to educate patients and primary care providers about monitoring mental well-being post COVID-19. KW - health care KW - public health KW - quality of life Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357174 VL - 13 ER - TY - JOUR A1 - Helmer, Philipp A1 - Rodemers, Philipp A1 - Hottenrott, Sebastian A1 - Leppich, Robert A1 - Helwich, Maja A1 - Pryss, Rüdiger A1 - Kranke, Peter A1 - Meybohm, Patrick A1 - Winkler, Bernd E. A1 - Sammeth, Michael T1 - Evaluating blood oxygen saturation measurements by popular fitness trackers in postoperative patients: a prospective clinical trial JF - iScience N2 - Summary Blood oxygen saturation is an important clinical parameter, especially in postoperative hospitalized patients, monitored in clinical practice by arterial blood gas (ABG) and/or pulse oximetry that both are not suitable for a long-term continuous monitoring of patients during the entire hospital stay, or beyond. Technological advances developed recently for consumer-grade fitness trackers could—at least in theory—help to fill in this gap, but benchmarks on the applicability and accuracy of these technologies in hospitalized patients are currently lacking. We therefore conducted at the postanaesthesia care unit under controlled settings a prospective clinical trial with 201 patients, comparing in total >1,000 oxygen blood saturation measurements by fitness trackers of three brands with the ABG gold standard and with pulse oximetry. Our results suggest that, despite of an overall still tolerable measuring accuracy, comparatively high dropout rates severely limit the possibilities of employing fitness trackers, particularly during the immediate postoperative period of hospitalized patients. Highlights •The accuracy of O2 measurements by fitness trackers is tolerable (RMSE ≲4%) •Correlation with arterial blood gas measurements is fair to moderate (PCC = [0.46; 0.64]) •Dropout rates of fitness trackers during O2 monitoring are high (∼1/3 values missing) •Fitness trackers cannot be recommended for O2 measuring during critical monitoring KW - multidisciplinary KW - health sciences KW - clinical measurement in health technology KW - bioelectronics KW - fitness trackers Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-349913 SN - 2589-0042 VL - 26 IS - 11 ER -